Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Taylor B. Smallwood & Richard J. Clark. (2021) Advances in venom peptide drug discovery: where are we at and where are we heading?. Expert Opinion on Drug Discovery 16:10, pages 1163-1173.
Read now
Read now
André J. Scheen. (2017) Dulaglutide for the treatment of type 2 diabetes. Expert Opinion on Biological Therapy 17:4, pages 485-496.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2016) Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opinion on Investigational Drugs 25:10, pages 1167-1179.
Read now
Read now
Eun Ji Park, Sung Mook Lim, Kang Choon Lee & Dong Hee Na. (2016) Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015). Expert Opinion on Therapeutic Patents 26:7, pages 833-842.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2016) An overview of new GLP-1 receptor agonists for type 2 diabetes. Expert Opinion on Investigational Drugs 25:2, pages 145-158.
Read now
Read now
Yunpeng Cai, Liangming Wei, Liuqing Ma, Xiwen Huang, Anqi Tao, Zhenguo Liu & Weien Yuan. (2013) Long-acting preparations of exenatide. Drug Design, Development and Therapy 7, pages 963-970.
Read now
Read now
Thomas Forst & Andreas Pfützner. (2013) Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 14:16, pages 2281-2296.
Read now
Read now
Giuseppe Derosa & Pamela Maffioli. (2012) Optimizing glycemic control: clinical utility of exenatide prolonged release injection. Research and Reports in Endocrine Disorders 2, pages 41-51.
Read now
Read now
Christophe EM De Block & Luc F Van Gaal. (2012) Efficacy and safety of exenatide once weekly: an overview of the DURATION trials. Expert Review of Endocrinology & Metabolism 7:6, pages 611-623.
Read now
Read now
Alan J Garber. (2012) Novel GLP-1 receptor agonists for diabetes. Expert Opinion on Investigational Drugs 21:1, pages 45-57.
Read now
Read now
Glenn F King. (2011) Venoms as a platform for human drugs: translating toxins into therapeutics. Expert Opinion on Biological Therapy 11:11, pages 1469-1484.
Read now
Read now
Sheila A Doggrell. (2011) Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials. Expert Opinion on Pharmacotherapy 12:13, pages 2055-2067.
Read now
Read now
Thomas D Aicher, Steven A Boyd, Maralee McVean & Anthony Celeste. (2010) Novel therapeutics and targets for the treatment of diabetes. Expert Review of Clinical Pharmacology 3:2, pages 209-229.
Read now
Read now
Articles from other publishers (24)
Jing-Yue Wang, Quan-Wei Wang, Xin-Yu Yang, Wei Yang, Dong-Rui Li, Jing-Yu Jin, Hui-Cong Zhang & Xian-Feng Zhang. (2023) GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach. Frontiers in Endocrinology 14.
Crossref
Crossref
Maria Elena de Lima & Kênia Pedrosa Nunes. (2022) Drugs from Animal Venoms: Overcoming the Challenges to Treat Erectile
Dysfunction. Venoms and Toxins 2:2.
Crossref
Crossref
Hussein Herz, Yang Song, Yuanchao Ye, Liping Tian, Benjamin Linden, Marwa Abu El Haija, Yi Chu, Justin L. Grobe, Randall W. Lengeling & Mohamad Mokadem. (2021) NSAID-Induced Enteropathy Affects Regulation of Hepatic Glucose Production by Decreasing GLP-1 Secretion. Nutrients 14:1, pages 120.
Crossref
Crossref
Volker Herzig, Ben Cristofori-Armstrong, Mathilde R. Israel, Samantha A. Nixon, Irina Vetter & Glenn F. King. (2020) Animal toxins — Nature’s evolutionary-refined toolkit for basic research and drug discovery. Biochemical Pharmacology 181, pages 114096.
Crossref
Crossref
Cristian Guja & Andrada Mihai. (2017) Exenatide QW – New Perspectives 5 Years after its First Use. Romanian Journal of Diabetes Nutrition and Metabolic Diseases 24:4, pages 281-287.
Crossref
Crossref
Chris de Graaf, Dan Donnelly, Denise Wootten, Jesper Lau, Patrick M. Sexton, Laurence J. Miller, Jung-Mo Ahn, Jiayu Liao, Madeleine M. Fletcher, Dehua Yang, Alastair J. H. Brown, Caihong Zhou, Jiejie Deng & Ming-Wei Wang. (2016) Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes. Pharmacological Reviews 68:4, pages 954-1013.
Crossref
Crossref
Laurence G. Trahair, Michael Horowitz, Trygve Hausken, Christine Feinle-Bisset, Christopher K. Rayner & Karen L. Jones. (2014) Effects of Exogenous Glucagon-Like Peptide-1 on the Blood Pressure, Heart Rate, Mesenteric Blood Flow, and Glycemic Responses to Intraduodenal Glucose in Healthy Older Subjects. The Journal of Clinical Endocrinology & Metabolism 99:12, pages E2628-E2634.
Crossref
Crossref
Chang Yu Pan, Ping Han, Xiaoming Liu, Shengli Yan, Ping Feng, Zhiguang Zhou, Xiaofeng Lv, Hui Tian, Yang Jin Kui, Benli Su, Shuhua Shang & Elisabeth Niemoeller. (2014) Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double‐blind, placebo‐controlled, 24‐week trial (GetGoal‐M‐Asia). Diabetes/Metabolism Research and Reviews 30:8, pages 726-735.
Crossref
Crossref
G. B. Bolli & D. R. Owens. (2014) Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 16:7, pages 588-601.
Crossref
Crossref
Ulrich Werner. (2014) Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying – preclinical evidence. Journal of Diabetes and its Complications 28:1, pages 110-114.
Crossref
Crossref
Giuseppe Derosa & Pamela Maffioli. 2014. Integrative Weight Management. Integrative Weight Management
261
277
.
Michael Horowitz, Christopher K. Rayner & Karen L. Jones. (2013) Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes. Advances in Therapy 30:2, pages 81-101.
Crossref
Crossref
Sayaka Fukuda-Tsuru, Jun Anabuki, Yuji Abe, Kumiko Yoshida & Shinichi Ishii. (2012) A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. European Journal of Pharmacology 696:1-3, pages 194-202.
Crossref
Crossref
Jonathan D Roth, Mary R Erickson, Steve Chen & David G Parkes. (2012) GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities. British Journal of Pharmacology 166:1, pages 121-136.
Crossref
Crossref
Maria Tzefos, Kira Harris & Adriane Brackett. (2012) Clinical Efficacy and Safety of Once-Weekly Glucagon-Like Peptide-1 Agonists in Development for Treatment of Type 2 Diabetes Mellitus in Adults. Annals of Pharmacotherapy 46:1, pages 68-78.
Crossref
Crossref
Tetsuhiro Tanaka, Masaomi Nangaku & Akira Nishiyama. (2011) The role of incretins in salt-sensitive hypertension. Current Opinion in Nephrology & Hypertension 20:5, pages 476-481.
Crossref
Crossref
Riccardo Perfetti. (2011) Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics. Diabetes Technology & Therapeutics 13:9, pages 873-881.
Crossref
Crossref
Nicole R Pinelli & Kathryn M Hurren. (2011) Efficacy and Safety of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared with Exenatide Twice Daily and Sitagliptin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Annals of Pharmacotherapy 45:7-8, pages 850-860.
Crossref
Crossref
S. Madsbad, U. Kielgast, M. Asmar, C. F. Deacon, S. S. Torekov & J. J. Holst. (2011) An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future. Diabetes, Obesity and Metabolism 13:5, pages 394-407.
Crossref
Crossref
Remy Burcelin, Cendrine Cabou, Christophe Magnan & Pierre Gourdy. 2011. Metabolic Syndrome. Metabolic Syndrome
279
325
.
Irina Vetter, Jasmine L. Davis, Lachlan D. Rash, Raveendra Anangi, Mehdi Mobli, Paul F. Alewood, Richard J. Lewis & Glenn F. King. (2010) Venomics: a new paradigm for natural products-based drug discovery. Amino Acids 40:1, pages 15-28.
Crossref
Crossref
Que Liu, Lisa Adams, Anatoly Broyde, Rayne Fernandez, Alain D Baron & David G Parkes. (2010) The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. Cardiovascular Diabetology 9:1.
Crossref
Crossref
Taichi Ueda, Takaomi Ito, Kazuyoshi Tomita, Hiroko Togame, Masataka Fumoto, Kenji Asakura, Takeo Oshima, Shin-Ichiro Nishimura & Kohji Hanasaki. (2010) Identification of glycosylated exendin-4 analogue with prolonged blood glucose-lowering activity through glycosylation scanning substitution. Bioorganic & Medicinal Chemistry Letters 20:15, pages 4631-4634.
Crossref
Crossref
Rudy Bilous & Richard Donnelly. 2010. Handbook of Diabetes. Handbook of Diabetes
79
86
.